{
    "clinical_study": {
        "@rank": "67255", 
        "arm_group": [
            {
                "arm_group_label": "Teinted sunscream", 
                "arm_group_type": "Experimental", 
                "description": "UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)"
            }, 
            {
                "arm_group_label": "Regular sunscream", 
                "arm_group_type": "Active Comparator", 
                "description": "UVA and UVB protection"
            }
        ], 
        "brief_summary": {
            "textblock": "Main objective is to show that a photoprotective sunscreen having a protection against the\n      visible light is more effective than a sunscreen having the same UVA AND UVB protection but\n      with a low (weak) protection against the visible, to prevent the relapses of the melasma\n      during the summertime."
        }, 
        "brief_title": "Prevention of Melasma Relapse During Summertime", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Actual"
        }, 
        "condition": "Melasma", 
        "condition_browse": {
            "mesh_term": "Melanosis"
        }, 
        "detailed_description": {
            "textblock": "40 melasma affected women will be included and randomized in two parallel groups (one group\n      protected by a UVA+UVB+visible extended sunscreen and one group group protected by a UVA+UVB\n      sunscreen).\n\n      There will be 3 visits: Baseline, T2.5months and T5months (final visit).\n\n      Products application frequency: twice daily(morning and afternoon) and additional\n      applications every 2 hours in case of solar exposure.\n\n      Main evaluation criterion: the MASI score assessed from standardized photographs (system\n      VISIA, Canfield Scientific, USA) at Baseline, middle and end of study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Melasma\n\n        Exclusion Criteria:\n\n          -  Other pigmentary disorders associated (including PIH)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061839", 
            "org_study_id": "2013-A00073-42"
        }, 
        "intervention": [
            {
                "arm_group_label": "Teinted sunscream", 
                "intervention_name": "Sunscream with visible light protection", 
                "intervention_type": "Other"
            }, 
            {
                "arm_group_label": "Regular sunscream", 
                "intervention_name": "Sunscream", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 12, 2014", 
        "number_of_arms": "2", 
        "official_title": "Prevention of Melasma Relapse During Summertime", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: ANSM - Agence National de S\u00e9curit\u00e9 du M\u00e9dicament", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "MASI scores are evaluated by two physicians blinded to the treatment received on standardized pictures taken before treatment and after 6 months of summer period", 
            "measure": "Comparison between MASI scores before prevention treatment and after 6 months", 
            "safety_issue": "No", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061839"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Centre de Pharmacologie Clinique Applique a la Dermatologie", 
        "sponsors": {
            "collaborator": {
                "agency": "BIODERMA", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Centre de Pharmacologie Clinique Applique a la Dermatologie", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}